UTRN and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: The beneficial effects of combining such therapies should theoretically be additive with the prediction that the cumulative increase in utrophin levels would be sufficient to substantially prevent or delay the phenotypes associated with dystrophin deficiency.